Journal ArticleDOI
Pertuzumab plus trastuzumab and real-world standard of care (SOC) for patients (pts) with treatment refractory metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification (amp) confirmed by tumor tissue or ctDNA analysis (TRIUMPH, EPOC1602).
Wataru Okamoto,Yoshiaki Nakamura,Takeshi Kato,Taito Esaki,Masato Komoda,Ken Kato,Yoshito Komatsu,Toshiki Masuishi,Tomohiro Nishina,Kentaro Sawada,Hiroya Taniguchi,Nozomu Fuse,Shogo Nomura,Makoto Fukui,Steven R. Olsen,Justin I. Odegaard,Akihiro Sato,Satoshi Fujii,Atsushi Ohtsu,Takayuki Yoshino +19 more
Reads0
Chats0
TLDR
A phase 2 trial to evaluate the efficacy and safety of P+T for RASwt mCRC pts with HER2 amp in either tumor tissue or ctDNA shows that complete ct DNA genotyping identifies pts most likely to benefit from dual HER2 blockade and can be used to monitor response and detect actionable resistance biomarkers.Abstract:
3555Background: HER2 amp occurs in 1-4% of mCRC pts. Two single arm phase 2 studies, HERACLES and MyPathway, showed efficacy for dual HER2-targeted therapy in pts with RAS wild type (RAS wt) mCRC w...read more
Citations
More filters
Journal ArticleDOI
Diagnosis and Treatment of ERBB2-Positive Metastatic Colorectal Cancer: A Review.
TL;DR: The results of this review suggest the ERBB2 receptor is a promising target for patients with metastatic colorectal cancer; however, to date, no therapies are approved for use in this patient population.
Journal ArticleDOI
SCRUM-Japan GI-SCREEN and MONSTAR-SCREEN: Path to the realization of biomarker-guided precision oncology in advanced solid tumors.
Yoshiaki Nakamura,Takao Fujisawa,Hiroya Taniguchi,Hideaki Bando,Wataru Okamoto,Katsuya Tsuchihara,Takayuki Yoshino,Atsushi Ohtsu +7 more
TL;DR: In this article, the authors describe the path to the realization of cancer precision medicine for patients with advanced solid tumors based on the SCRUM-Japan GI-ScREEN and MONSTAR-SCREEN platforms.
Journal ArticleDOI
Prognostic and predictive molecular biomarkers in advanced colorectal cancer
TL;DR: In this paper , the authors focus on all these prognostic and predictive biomarkers, analyzing data from the most important clinical trials of the last years, and also try to rank them according to their prognosis and predictive power.
Journal ArticleDOI
Biomarkers in Metastatic Colorectal Cancer: Status Quo and Future Perspective
TL;DR: In this paper , the authors provide an overview about therapeutic relevant and established biomarkers but also shed light on potential promising markers that may help us to better tailor therapy to the individual colorectal cancer patient in the near future.
Journal ArticleDOI
Prognostic and predictive molecular biomarkers in advanced colorectal cancer.
TL;DR: This Review focuses on all the prognostic and predictive biomarkers of colorectal cancer, analyzing data from the most important clinical trials of the last years, and tries to rank them according to their prognosis and predictive power.